EuroPCR 2023 Hotlines/Late-Breaking Trials: focus on stent technology

Session comprising selected EuroPCR 2023 Late-Breaking Trial submissions

Anchorperson: S. Windecker

Spokesperson: R. Waksman

Summary

If you would like to learn more about the latest findings on stent techhnology, check-out this session in which speakers reviewed a series of recent trials, among them: 12-month primary endpoint outcomes of the BIOADAPTOR-RCT; Final 5-year results from the blinded ABSORB IV trial ; BIOMAG-I: 1-year clinical outcome of the resorbable magnesium scaffold-DREAMS 3G; Biodegradable polymer vs. Polymer-free ultrathin sirolimus-eluting stents (HOST-IDEA, and long-term outcome after resorbable magnesium scaffold implementation (SHERPA-MAGIC study).

Presentations available when logged in:

12-month primary endpoint outcomes of the BIOADAPTOR-RCT
Final five-year results from the blinded ABSORB IV trial
BIOMAG-I: one-year clinical outcome of the resorbable magnesium scaffold-DREAMS 3G
Long-term outcome after resorbable magnesium scaffold implantation
Biodegradable polymer vs. polymer-free ultrathin sirolimus-eluting stents
Clinical outcomes at three years from first-in-man LEADERS FREE III trial
Randomised trial of biolimus DEB for in-stent restenosis: the REFORM study

Your free My PCR account will enable you to:

Become a PCR Companion
Access slide presentations from PCR Courses
Watch session videos and LIVE cases
Discuss cases with your peers
Submit and register for PCR Courses
Register for and view PCR Webinars
Read a selection of articles in EuroIntervention
And more…

EuroPCR 2023 Hotlines/Late-Breaking Trials: focus on stent technology

Session comprising selected EuroPCR 2023 Late-Breaking Trial submissions

Log in or create account for free